Calendar    

Webinar Series - Engineered Cell Therapies & Environmental Assessments: CTA Is Just The Start. How To Navigate The New Substance Notification Regulations for Organisms

Description

When it comes time to file a Clinical Trial Application for new cell or gene therapy products, a New Substance Notification Regulation (Organism) Schedule 1 form may also need to be filed with Environment and Climate Control Canada (ECCC). This is often true for products touched by biotech, including vector-modified or gene edited cells, such as CAR-T. But what necessitates the submission of this extra form? Why does it need to go to ECCC, where other forms are sent to Health Canada? And what’s being done to make the CTA process smoother for innovators? Tune in to hear Dr. Sowmya Viswanathan explain her work on clarifying the NSNR(O) process.

Join us at 12PM.

Register here.

Details
  • 20/02/2020

Best Practices for Therapeutic Translation: Optimizing Pre-Clinical Research Rigor and Reproducibility

Description

 Workshop Summary: 

The translation of discoveries into new clinical therapies is a multi-step process that requires careful planning and rigor at all stages. The Stem Cell Network and BioCanRx are excited to host, in conjunction with our partner sponsoring organizations CellCAN, OIRM and ThéCell, a new 2-day training workshop that will provide attendees with foundational knowledge in two key areas that are critical to establishing the robust experimental evidence necessary for successful clinical or commercial translation: Quality Best Practices and Preclinical Experimental Design and Reporting, both of which are cornerstones in achieving reproducibility, reducing experimental waste and improving the translational prospects of a discovery.

When? February 25 & 26, 2020

Where? Chestnut Conference Centre, Toronto, Canada

For more information and travel award opportunities. 

 

 

Details
  • 25/02/2020

Webinar Series - Bioprinting at the nexus of medical device, biologic and cell therapy regulation, with Sam Wadsworth, Aspect Biosystems

Description

Aspect Biosystems develops 3D-printed structures that incorporate biomaterials, cells, and software. Sam Wadsworth will discuss the various factors that go into regulations of two of their research products: meniscus tissues for knee injury, and pancreatic islet tissue for type I diabetes. Quality control, clinical and non-clinical studies, manufacturing sites, risk mitigation, and supply chain are a few of the issues that will be addressed.

Join us at 12PM (EST).

Register here. 


Details
  • 19/03/2020

2021 Strategic Forum

Description

CellCAN is proud to announce that it will be hosting a third edition of the Cell & Gene Therapy Revolution Strategic Forum in Ottawa, from March 15 to 17, 2021!

More information available here.

Details
  • 15/03/2021

Connect with a network of Canadian researchers, clinicians, regulatory experts and HQP from coast to coast, through our platforms, workshops and events.

13 NETWORK AFFILIATES. 25 PARTNER ORGANIZATIONS. 181 NETWORK COLLABORATORS.